Ecosystem of Healthcare Industry Research Report: By Disease Type, Payment Mechanism, Diagnostic Equipment Type, In-vitro Diagnostic Technology, Channel, Hospital Bed Capacity, Payer Type, Provider Type, Care Pathway Stage, Disease Stage Type, Regional Insight (U.S., U.K, France, Germany, China, Japan, Singapore) – Growth Prospect and Forecast to 2024

Chapter 1. Research Background

1.1 Research Objectives

1.2 Market Definition

1.3 Research Scope

1.3.1 Market Segmentation by Disease Type

1.3.2 Market Segmentation by Payment Mechanism

1.3.3 Market Segmentation by Diagnostic Equipment Type

1.3.4 Market Segmentation by In-vitro Diagnostic (IVD) Technology

1.3.5 Market Segmentation by Channel

1.3.6 Market Segmentation by Hospital Bed Capacity

1.3.7 Market Segmentation by Payer Type

1.3.8 Market Segmentation by Provider Type

1.3.9 Market Segmentation by Care Pathway Stage

1.3.10 Market Segmentation by Disease Stage

1.3.11 Market Segmentation by Country

1.3.12 Analysis Period

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By country

2.2.1.2 By industry participant

2.2.1.3 By company type

2.3 Market Size Estimation

2.4 Data Triangulation

2.5 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

4.1 Definition of Market Segments

4.1.1 By Disease Type

4.1.1.1 Cardiovascular and circulatory diseases

4.1.1.2 Neuropsychiatric disorders

4.1.1.3 CRD

4.1.1.4 Diabetes, blood, and endocrine disorders

4.1.1.5 Cancer

4.1.1.6 Chronic liver diseases

4.1.1.7 Musculoskeletal disorders

4.1.1.8 Others

4.1.2 By Payment Mechanism

4.1.2.1 Fee-for-service

4.1.2.2 Self-pay

4.1.2.3 Value-based reimbursement

4.1.3 By Diagnostic Equipment Type

4.1.3.1 X-Ray

4.1.3.2 MRI

4.1.3.3 Ultrasound

4.1.3.4 CT

4.1.3.5 Mammography

4.1.3.6 Endoscopes

4.1.3.7 Others

4.1.4 By IVD Technology

4.1.4.1 Immunoassay/immunochemistry

4.1.4.2 Clinical chemistry

4.1.4.3 Molecular diagnostics

4.1.4.4 Microbiology

4.1.4.5 Hematology

4.1.4.6 Urinalysis

4.1.4.7 Others

4.1.5 By Channel

4.1.5.1 Non-profit

4.1.5.2 For-profit

4.1.5.3 State/local

4.1.5.4 Others

4.1.6 By Hospital Bed Capacity

4.1.6.1 <100

4.1.6.2 100-199

4.1.6.3 200-499

4.1.6.4 >=500

4.1.7 By Payer Type

4.1.7.1 Medicare

4.1.7.2 Medicaid

4.1.7.3 Private payers

4.1.7.4 Others

4.1.8 By Provider Type

4.1.8.1 Primary care

4.1.8.2 Nursing care

4.1.8.3 Specialty care

4.1.8.3.1 Endocrinology

4.1.8.3.2 Gastroenterology

4.1.8.3.3 Hematology

4.1.8.3.4 Neurology

4.1.8.3.5 Oncology

4.1.8.3.6 Urology

4.1.8.3.7 Cardiology

4.1.8.3.8 Gynecology

4.1.8.3.9 Others

4.1.9 By Care Pathway Stage

4.1.9.1 Primary prevention

4.1.9.2 Early management

4.1.9.3 Treatment

4.1.9.4 Prevention and management of complications

4.1.10 By Disease Stage

4.1.10.1 Chronic

4.1.10.2 Acute

4.2 Market Dynamics

4.2.1 Trends

4.2.1.1 Increasing number of collaborations and partnerships

4.2.1.2 Rise in number of mergers and acquisitions

4.2.1.3 Increasing number of product launches

4.2.1.4 Integration of biosensors in healthcare industry

4.2.1.5 Integration of artificial intelligence/machine learning

4.2.2 Drivers

4.2.2.1 Increasing prevalence of chronic diseases

4.2.2.2 Government initiatives and better healthcare infrastructure

4.2.2.3 Increasing GDP and healthcare expenditure

4.2.2.4 Rise in the adoption of healthcare insurance

4.2.2.5 Surge in geriatric population

4.2.2.6 Growing demand of IVD tests

4.2.2.7 Digitalization in healthcare industry

4.2.2.8 Impact analysis of drivers on market forecast

4.2.3 Restraints

4.2.3.1 Stringent regulations

4.2.3.2 High cost of development and management of devices

4.2.3.3 Product recalls

4.2.3.4 Impact analysis of restraints on market forecast

4.3 Porter’s Five Forces Analysis

4.4 Regulatory Overview of Healthcare Industry

4.4.1 U.S.

4.4.1.1 Regulations for pharmaceutical products

4.4.1.2 Regulations for healthcare insurance

4.4.1.3 Regulations for medical devices

4.4.2 Europe

4.4.2.1 Regulations for pharmaceutical products and medical devices

4.4.2.2 Regulations for healthcare insurance

4.4.3 APAC

4.4.3.1 China

4.4.3.1.1 Regulations for pharmaceutical products and medical devices

4.4.3.1.2 Regulations for healthcare insurance

4.4.3.2 Japan

4.4.3.2.1 Regulations for pharmaceutical products and medical devices

4.4.3.2.2 Regulations for healthcare insurance

4.5 PESTLE Analysis

4.6 Pricing Analysis

4.6.1 X-Ray Imaging Systems

4.6.2 MRI Systems

4.6.3 Ultrasound Systems

4.6.4 CT Scanners

4.6.5 Nuclear Imaging Systems

Chapter 5. U.S. Market Size and Forecast

5.1 By Disease Type

5.2 By Payment Mechanism

5.3 By Diagnostic Equipment Type

5.4 By IVD Technology

5.5 By Channel

5.6 By Hospital Bed Capacity

5.7 By Payer Type

5.8 By Provider Type

5.8.1 Healthcare Industry for Specialty Care, by Disease Type

5.9 By Care Pathway Stage

5.10 By Disease Stage

Chapter 6. Germany Market Size and Forecast

6.1 By Disease Type

6.2 By Payment Mechanism

6.3 By Diagnostic Equipment Type

6.4 By IVD Technology

6.5 By Channel

6.6 By Hospital Bed Capacity

6.7 By Provider Type

6.7.1 Healthcare Industry for Specialty Care, by Disease Type

6.8 By Care Pathway Stage

6.9 By Disease Stage

Chapter 7. U.K. Market Size and Forecast

7.1 By Disease Type

7.2 By Payment Mechanism

7.3 By Diagnostic Equipment Type

7.4 By IVD Technology

7.5 By Channel

7.6 By Hospital Bed Capacity

7.7 By Provider Type

7.7.1 Healthcare Industry for Specialty Care, by Disease Type

7.8 By Care Pathway Stage

7.9 By Disease Stage

Chapter 8. France Market Size and Forecast

8.1 By Disease Type

8.2 By Payment Mechanism

8.3 By Diagnostic Equipment Type

8.4 By IVD Technology

8.5 By Channel

8.6 By Hospital Bed Capacity

8.7 By Provider Type

8.7.1 Healthcare Industry for Specialty Care, by Disease Type

8.8 By Care Pathway Stage

8.9 By Disease Stage

Chapter 9. China Market Size and Forecast

9.1 By Disease Type

9.2 By Payment Mechanism

9.3 By Diagnostic Equipment Type

9.4 By IVD Technology

9.5 By Channel

9.6 By Hospital Bed Capacity

9.7 By Provider Type

9.7.1 Healthcare Industry for Specialty Care, by Disease Type

9.8 By Care Pathway Stage

9.9 By Disease Stage

Chapter 10. Japan Market Size and Forecast

10.1 By Disease Type

10.2 By Payment Mechanism

10.3 By Diagnostic Equipment Type

10.4 By IVD Technology

10.5 By Channel

10.6 By Hospital Bed Capacity

10.7 By Provider Type

10.7.1 Healthcare Industry for Specialty Care, by Disease Type

10.8 By Care Pathway Stage

10.9 By Disease Stage

Chapter 11. Singapore Market Size and Forecast

11.1 By Disease Type

11.2 By Payment Mechanism

11.3 By Diagnostic Equipment Type

11.4 By IVD Technology

11.5 By Channel

11.6 By Hospital Bed Capacity

11.7 By Provider Type

11.7.1 Healthcare Industry for Specialty Care, by Disease Type

11.8 By Care Pathway Stage

11.9 By Disease Stage

Chapter 12. Competitive Landscape

12.1 Market Share Analysis

12.1.1 Diagnostic Imaging Market

12.1.2 IVD Market

12.2 Global Strategic Developments of Key Players

12.2.1 Product Launches and Approvals

12.2.2 Collaborations

12.2.3 Acquisitions

Chapter 13. Company Profiles

13.1 Diagnostic Equipment Players

13.1.1 General Electric Company

13.1.1.1 Business overview

13.1.1.2 Product and service offerings

13.1.1.3 Key financial summary

13.1.2 Koninklijke Philips N.V.

13.1.2.1 Business overview

13.1.2.2 Product and service offerings

13.1.2.3 Key financial summary

13.1.3 Siemens AG

13.1.3.1 Business overview

13.1.3.2 Product and service offerings

13.1.3.3 Key financial summary

13.1.4 Canon Medical Systems Corporation

13.1.4.1 Business overview

13.1.4.2 Product and service offerings

13.1.4.3 Key financial summary

13.1.5 Shimadzu Corporation

13.1.5.1 Business overview

13.1.5.2 Product and service offerings

13.1.5.3 Key financial summary

13.1.6 Carestream Health Inc.

13.1.6.1 Business overview

13.1.6.2 Product and service offerings

13.1.7 Esaote S.p.A.

13.1.7.1 Business overview

13.1.7.2 Product and service offerings

13.1.8 FUJIFILM Holdings Corporation

13.1.8.1 Business overview

13.1.8.2 Product and service offerings

13.1.8.3 Key financial summary

13.1.9 Samsung Electronics Co. Ltd.

13.1.9.1 Business overview

13.1.9.2 Product and service offerings

13.1.9.3 Key financial summary

13.1.10 Hologic Inc.

13.1.10.1 Business overview

13.1.10.2 Product and service offerings

13.1.10.3 Key financial summary

13.2 IVD Players

13.2.1 bioMérieux S.A.

13.2.1.1 Business overview

13.2.1.2 Product and service offerings

13.2.1.3 Key financial summary

13.2.2 Bio-Rad Laboratories Inc.

13.2.2.1 Business overview

13.2.2.2 Product and service offerings

13.2.2.3 Key financial summary

13.2.3 Thermo Fisher Scientific Inc.

13.2.3.1 Business overview

13.2.3.2 Product and service offerings

13.2.3.3 Key financial summary

13.2.4 Becton, Dickinson and Company

13.2.4.1 Business overview

13.2.4.2 Product and service offerings

13.2.4.3 Key financial summary

13.2.5 Danaher Corporation

13.2.5.1 Business overview

13.2.5.2 Product and service offerings

13.2.5.3 Key financial summary

13.2.6 Abbott Laboratories

13.2.6.1 Business overview

13.2.6.2 Product and service offerings

13.2.6.3 Key financial summary

13.2.7 Siemens AG

13.2.7.1 Business overview

13.2.7.2 Product and service offerings

13.2.7.3 Key financial summary

13.2.8 QIAGEN N.V.

13.2.8.1 Business overview

13.2.8.2 Product and service offerings

13.2.8.3 Key financial summary

13.2.9 DiaSorin S.p.A.

13.2.9.1 Business overview

13.2.9.2 Product and Service Offerings

13.2.9.3 Key financial summary

13.2.10 Ortho-Clinical Diagnostics Inc.

13.2.10.1 Business overview

13.2.10.2 Product and service offerings

13.2.11 F. Hoffmann-La Roche Ltd.

13.2.11.1 Business overview

13.2.11.2 Product and service offerings

13.2.11.3 Key financial summary

13.2.12 Agilent Technologies Inc.

13.2.12.1 Business overview

13.2.12.2 Product and service offerings

13.2.12.3 Key financial summary

Chapter 14. Appendix

14.1 Abbreviations

14.2 Sources and References

14.3 Related Reports

 

LIST OF TABLES

 

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 KEY BODIES WITH REGULATORY AUTHORITY OVER HEALTH CARE IN THE U.S.

TABLE 5 PRICE RANGE OF SOME MAJORLY USED X-RAY SYSTEMS

TABLE 6 PRICE RANGE OF SOME MAJORLY USED MRI SYSTEMS

TABLE 7 PRICE RANGE OF SOME MAJORLY USED ULTRASOUND SYSTEMS

TABLE 8 PRICE RANGE OF SOME MAJORLY USED CT SCANNERS

TABLE 9 PRICE RANGE OF SOME MAJORLY USED NUCLEAR IMAGING SYSTEMS

TABLE 10 U.S. HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2024)

TABLE 11 U.S. HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2025–2030)

TABLE 12 U.S. HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2024)

TABLE 13 U.S. HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2025–2030)

TABLE 14 U.S. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2024)

TABLE 15 U.S. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2025–2030)

TABLE 16 U.S. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2024)

TABLE 17 U.S. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2025–2030)

TABLE 18 U.S. HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2024)

TABLE 19 U.S. HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2025–2030)

TABLE 20 U.S. HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2024)

TABLE 21 U.S. HEALTHCARE INDUSTRY, BY CHANNEL, $B (2025–2030)

TABLE 22 U.S. HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2024)

TABLE 23 U.S. HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2025–2030)

TABLE 24 U.S. HEALTHCARE INDUSTRY, BY PAYER TYPE, $B (2019–2024)

TABLE 25 U.S. HEALTHCARE INDUSTRY, BY PAYER TYPE, $B (2025–2030)

TABLE 26 U.S. HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2024)

TABLE 27 U.S. HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2025–2030)

TABLE 28 U.S. HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2024)

TABLE 29 U.S. HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2025–2030)

TABLE 30 U.S. HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2024)

TABLE 31 U.S. HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2025–2030)

TABLE 32 U.S. HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2024)

TABLE 33 U.S. HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2025–2030)

TABLE 34 GERMANY HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2024)

TABLE 35 GERMANY HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2025–2030)

TABLE 36 GERMANY HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2024)

TABLE 37 GERMANY HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2025–2030)

TABLE 38 GERMANY HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2024)

TABLE 39 GERMANY HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2025–2030)

TABLE 40 GERMANY HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2024)

TABLE 41 GERMANY HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2025–2030)

TABLE 42 GERMANY HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2024)

TABLE 43 GERMANY HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2025–2030)

TABLE 44 GERMANY HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2024)

TABLE 45 GERMANY HEALTHCARE INDUSTRY, BY CHANNEL, $B (2025–2030)

TABLE 46 GERMANY HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2024)

TABLE 47 GERMANY HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2025–2030)

TABLE 48 GERMANY HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2024)

TABLE 49 GERMANY HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2025–2030)

TABLE 50 GERMANY HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2024)

TABLE 51 GERMANY HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2025–2030)

TABLE 52 GERMANY HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2024)

TABLE 53 GERMANY HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2025–2030)

TABLE 54 GERMANY HEALTHCARE INDUSTRY, BY DISEASE STAGE TYPE, $B (2019–2024)

TABLE 55 GERMANY HEALTHCARE INDUSTRY, BY DISEASE STAGE TYPE, $B (2025–2030)

TABLE 56 U.K. HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2024)

TABLE 57 U.K. HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2025–2030)

TABLE 58 U.K. HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2024)

TABLE 59 U.K. HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2025–2030)

TABLE 60 U.K. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2024)

TABLE 61 U.K. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2025–2030)

TABLE 62 U.K. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2024)

TABLE 63 U.K. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2025–2030)

TABLE 64 U.K. HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2024)

TABLE 65 U.K. HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2025–2030)

TABLE 66 U.K. HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2024)

TABLE 67 U.K. HEALTHCARE INDUSTRY, BY CHANNEL, $B (2025–2030)

TABLE 68 U.K. HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2024)

TABLE 69 U.K. HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2025–2030)

TABLE 70 U.K. HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2024)

TABLE 71 U.K. HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2025–2030)

TABLE 72 U.K. HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2024)

TABLE 73 U.K. HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2025–2030)

TABLE 74 U.K. HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2024)

TABLE 75 U.K. HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2025–2030)

TABLE 76 U.K. HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2024)

TABLE 77 U.K. HEALTHCARE INDUSTRY, BY DISEASE STAGE TYPE, $B (2025–2030)

TABLE 78 FRANCE HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2024)

TABLE 79 FRANCE HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2025–2030)

TABLE 80 FRANCE HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2024)

TABLE 81 FRANCE HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2025–2030)

TABLE 82 FRANCE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2024)

TABLE 83 FRANCE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2025–2030)

TABLE 84 FRANCE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2024)

TABLE 85 FRANCE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2025–2030)

TABLE 86 FRANCE HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2024)

TABLE 87 FRANCE HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2025–2030)

TABLE 88 FRANCE HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2024)

TABLE 89 FRANCE HEALTHCARE INDUSTRY, BY CHANNEL, $B (2025–2030)

TABLE 90 FRANCE HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2024)

TABLE 91 FRANCE HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2025–2030)

TABLE 92 FRANCE HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2024)

TABLE 93 FRANCE HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2025–2030)

TABLE 94 FRANCE. HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2024)

TABLE 95 FRANCE HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2025–2030)

TABLE 96 FRANCE HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2024)

TABLE 97 FRANCE HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2025–2030)

TABLE 98 FRANCE HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2024)

TABLE 99 FRANCE HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2025–2030)

TABLE 100 CHINA HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2024)

TABLE 101 CHINA HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2025–2030)

TABLE 102 CHINA HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2024)

TABLE 103 CHINA HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2025–2030)

TABLE 104 CHINA HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2024)

TABLE 105 CHINA HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2025–2030)

TABLE 106 CHINA HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2024)

TABLE 107 CHINA HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2024)

TABLE 108 CHINA HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2024)

TABLE 109 CHINA HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2025–2030)

TABLE 110 CHINA HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2024)

TABLE 111 CHINA HEALTHCARE INDUSTRY, BY CHANNEL, $B (2025–2030)

TABLE 112 CHINA HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2024)

TABLE 113 CHINA HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2025–2030)

TABLE 114 CHINA HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2024)

TABLE 115 CHINA HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2025–2030)

TABLE 116 CHINA HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2024)

TABLE 117 CHINA HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2025–2030)

TABLE 118 CHINA HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2024)

TABLE 119 CHINA HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2025–2030)

TABLE 120 CHINA HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2024)

TABLE 121 CHINA HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2025–2030)

TABLE 122 JAPAN HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2024)

TABLE 123 JAPAN HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2025–2030)

TABLE 124 JAPAN HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2024)

TABLE 125 JAPAN HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2025–2030)

TABLE 126 JAPAN HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2024)

TABLE 127 JAPAN HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2025–2030)

TABLE 128 JAPAN HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2024)

TABLE 129 JAPAN HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2025–2030)

TABLE 130 JAPAN HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2024)

TABLE 131 JAPAN HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2025–2030)

TABLE 132 JAPAN HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2024)

TABLE 133 JAPAN HEALTHCARE INDUSTRY, BY CHANNEL, $B (2025–2030)

TABLE 134 JAPAN HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2024)

TABLE 135 JAPAN HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2025–2030)

TABLE 136 JAPAN HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2024)

TABLE 137 JAPAN HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2025–2030)

TABLE 138 JAPAN HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2024)

TABLE 139 JAPAN HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2025–2030)

TABLE 140 JAPAN HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2024)

TABLE 141 JAPAN HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2025–2030)

TABLE 142 JAPAN HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2024)

TABLE 143 JAPAN HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2025–2030)

TABLE 144 SINGAPORE HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2024)

TABLE 145 SINGAPORE HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2025–2030)

TABLE 146 SINGAPORE HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2024)

TABLE 147 SINGAPORE HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2025–2030)

TABLE 148 SINGAPORE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2024)

TABLE 149 SINGAPORE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2025–2030)

TABLE 150 SINGAPORE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2024)

TABLE 151 SINGAPORE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2025–2030)

TABLE 152 SINGAPORE HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2024)

TABLE 153 SINGAPORE HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2025–2030)

TABLE 154 SINGAPORE HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2024)

TABLE 155 SINGAPORE HEALTHCARE INDUSTRY, BY CHANNEL, $B (2025–2030)

TABLE 156 SINGAPORE HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2024)

TABLE 157 SINGAPORE HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2025–2030)

TABLE 158 SINGAPORE HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2024)

TABLE 159 SINGAPORE HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2025–2030)

TABLE 160 SINGAPORE HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2024)

TABLE 161 SINGAPORE HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2025–2030)

TABLE 162 SINGAPORE HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2024)

TABLE 163 SINGAPORE HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2025–2030)

TABLE 164 SINGAPORE HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2024)

TABLE 165 SINGAPORE HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2025–2030)

TABLE 166 GENERAL ELECTRIC COMPANY – AT A GLANCE

TABLE 167 GENERAL ELECTRIC COMPANY – KEY FINANCIAL SUMMARY

TABLE 168 KONINKLIJKE PHILIPS N.V. – AT A GLANCE

TABLE 169 KONINKLIJKE PHILIPS N.V. – KEY FINANCIAL SUMMARY

TABLE 170 SIEMENS AG – AT A GLANCE

TABLE 171 SIEMENS AG – KEY FINANCIAL SUMMARY

TABLE 172 CANON MEDICAL SYSTEMS CORPORATION – AT A GLANCE

TABLE 173 CANON MEDICAL SYSTEMS CORPORATION – KEY FINANCIAL SUMMARY

TABLE 174 SHIMADZU CORPORATION – AT A GLANCE

TABLE 175 SHIMADZU CORPORATION – KEY FINANCIAL SUMMARY

TABLE 176 CARESTREAM HEALTH INC. – AT A GLANCE

TABLE 177 ESAOTE S.P.A. – AT A GLANCE

TABLE 178 FUJIFILM HOLDINGS CORPORATION – AT A GLANCE

TABLE 179 FUJIFILM HOLDINGS CORPORATION – KEY FINANCIAL SUMMARY

TABLE 180 SAMSUNG ELECTRONICS CO. LTD. – AT A GLANCE

TABLE 181 SAMSUNG ELECTRONICS CO. LTD. – KEY FINANCIAL SUMMARY

TABLE 182 HOLOGIC INC. – AT A GLANCE

TABLE 183 HOLOGIC INC. – KEY FINANCIAL SUMMARY

TABLE 184 BIOMÉRIEUX S.A. – AT A GLANCE

TABLE 185 BIOMÉRIEUX S.A. – KEY FINANCIAL SUMMARY

TABLE 186 BIO-RAD LABORATORIES INC. – AT A GLANCE

TABLE 187 BIO-RAD LABORATORIES INC. – KEY FINANCIAL SUMMARY

TABLE 188 THERMO FISHER SCIENTIFIC INC. – AT A GLANCE

TABLE 189 THERMO FISHER SCIENTIFIC INC. – KEY FINANCIAL SUMMARY

TABLE 190 BECTON, DICKINSON AND COMPANY – AT A GLANCE

TABLE 191 BECTON, DICKINSON AND COMPANY – KEY FINANCIAL SUMMARY

TABLE 192 DANAHER CORPORATION – AT A GLANCE

TABLE 193 DANAHER CORPORATION – KEY FINANCIAL SUMMARY

TABLE 194 ABBOTT LABORATORIES – AT A GLANCE

TABLE 195 ABBOTT LABORATORIES – KEY FINANCIAL SUMMARY

TABLE 196 SIEMENS AG – AT A GLANCE

TABLE 197 SIEMENS AG – KEY FINANCIAL SUMMARY

TABLE 198 QIAGEN N.V. - AT A GLANCE

TABLE 199 QIAGEN N.V. – KEY FINANCIAL SUMMARY

TABLE 200 DIASORIN S.P.A. - AT A GLANCE

TABLE 201 DIASORIN S.P.A. – KEY FINANCIAL SUMMARY

TABLE 202 ORTHO-CLINICAL DIAGNOSTICS INC. - AT A GLANCE

TABLE 203 F. HOFFMANN-LA ROCHE LTD. – AT A GLANCE

TABLE 204 F. HOFFMANN-LA ROCHE LTD. – KEY FINANCIAL SUMMARY

TABLE 205 AGILENT TECHNOLOGIES INC. – AT A GLANCE

TABLE 206 AGILENT TECHNOLOGIES INC. – KEY FINANCIAL SUMMARY

 

LIST OF FIGURES

 

FIG 1 RESEARCH SCOPE

FIG 2 RESEARCH METHODOLOGY

FIG 3 SPLIT OF PRIMARY AND SECONDARY RESEARCH, BY COUNTRY

FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY COUNTRY

FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY INDUSTRY PARTICIPANT

FIG 6 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE

FIG 7 DATA TRIANGULATION APPROACH

FIG 8 EXECUTIVE SUMMARY

FIG 9 GDP OF SOME MAJOR COUNTRIES, $M (2011 & 2017)

FIG 10 HEALTHCARE EXPENDITURE AS PERCENTAGE OF GDP (2011 & 2017)

FIG 11 BARGAINING POWER OF BUYERS

FIG 12 BARGAINING POWER OF SUPPLIERS

FIG 13 INTENSITY OF RIVALRY

FIG 14 THREAT OF NEW ENTRANTS

FIG 15 THREAT OF SUBSTITUTES

FIG 16 PESTLE ANALYSIS FOR THE U.S.

FIG 17 PESTLE ANALYSIS FOR THE U.K.

FIG 18 PESTLE ANALYSIS FOR FRANCE

FIG 19 PESTLE ANALYSIS FOR GERMANY

FIG 20 PESTLE ANALYSIS FOR CHINA

FIG 21 PESTLE ANALYSIS FOR JAPAN

FIG 22 PESTLE ANALYSIS FOR SINGAPORE

FIG 23 U.S. HEALTHCARE INDUSTRY SNAPSHOT

FIG 24 U.S. HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2030)

FIG 25 U.S. HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2030)

FIG 26 U.S. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2030)

FIG 27 U.S. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2030)

FIG 28 U.S. HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2030)

FIG 29 U.S. HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2030)

FIG 30 U.S. HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2030)

FIG 31 U.S. HEALTHCARE INDUSTRY, BY PAYER TYPE, $B (2019–2030)

FIG 32 U.S. HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2030)

FIG 33 U.S. HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2030)

FIG 34 U.S. HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2030)

FIG 35 U.S. HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2030)

FIG 36 GERMANY HEALTHCARE INDUSTRY SNAPSHOT

FIG 37 GERMANY HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2030)

FIG 38 GERMANY HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2030)

FIG 39 GERMANY HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2030)

FIG 40 GERMANY HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2030)

FIG 41 GERMANY HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2030)

FIG 42 GERMANY HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2030)

FIG 43 GERMANY HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2030)

FIG 44 GERMANY HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2030)

FIG 45 GERMANY HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2030)

FIG 46 GERMANY HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2030)

FIG 47 GERMANY HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2030)

FIG 48 U.K. HEALTHCARE INDUSTRY SNAPSHOT

FIG 49 U.K. HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2030)

FIG 50 U.K. HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2030)

FIG 51 U.K. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2030)

FIG 52 U.K. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2030)

FIG 53 U.K. HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2030)

FIG 54 U.K. HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2030)

FIG 55 U.K. HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2030)

FIG 56 U.K. HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2030)

FIG 57 U.K. HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2030)

FIG 58 U.K. HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2030)

FIG 59 U.K. HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2030)

FIG 60 FRANCE HEALTHCARE INDUSTRY SNAPSHOT

FIG 61 FRANCE HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2030)

FIG 62 FRANCE HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2030)

FIG 63 FRANCE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2030)

FIG 64 FRANCE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2030)

FIG 65 FRANCE HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2030)

FIG 66 FRANCE HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2030)

FIG 67 FRANCE HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2030)

FIG 68 FRANCE HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2030)

FIG 69 FRANCE HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2030)

FIG 70 FRANCE HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2030)

FIG 71 FRANCE HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2030)

FIG 72 CHINA HEALTHCARE INDUSTRY SNAPSHOT

FIG 73 CHINA HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2030)

FIG 74 CHINA HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2030)

FIG 75 CHINA HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2030)

FIG 76 CHINA HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2030)

FIG 77 CHINA HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2030)

FIG 78 CHINA HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2030)

FIG 79 CHINA HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2030)

FIG 80 CHINA HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2030)

FIG 81 CHINA HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2030)

FIG 82 CHINA HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2030)

FIG 83 CHINA HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2030)

FIG 84 JAPAN HEALTHCARE INDUSTRY SNAPSHOT

FIG 85 JAPAN HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2030)

FIG 86 JAPAN HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2030)

FIG 87 JAPAN HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2030)

FIG 88 JAPAN HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2030)

FIG 89 JAPAN HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2030)

FIG 90 JAPAN HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2030)

FIG 91 JAPAN HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2030)

FIG 92 JAPAN HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2030)

FIG 93 JAPAN HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2030)

FIG 94 JAPAN HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2030)

FIG 95 JAPAN HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2030)

FIG 96 SINGAPORE HEALTHCARE INDUSTRY SNAPSHOT

FIG 97 SINGAPORE HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2030)

FIG 98 SINGAPORE HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2030)

FIG 99 SINGAPORE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2030)

FIG 100 SINGAPORE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2030)

FIG 101 SINGAPORE HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2030)

FIG 102 SINGAPORE HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2030)

FIG 103 SINGAPORE HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2030)

FIG 104 SINGAPORE HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2030)

FIG 105 SINGAPORE HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2030)

FIG 106 SINGAPORE HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2030)

FIG 107 SINGAPORE HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2030)

FIG 108 MARKET SHARE ANALYSIS OF DIAGNOSTIC IMAGING EQUIPMENT IN THE U.S.

FIG 109 MARKET SHARE ANALYSIS OF DIAGNOSTIC IMAGING EQUIPMENT IN GERMANY

FIG 110 MARKET SHARE ANALYSIS OF DIAGNOSTIC IMAGING EQUIPMENT IN CHINA

FIG 111 MARKET SHARE ANALYSIS OF IVD IN THE U.S.

FIG 112 MARKET SHARE ANALYSIS OF IVD IN GERMANY

FIG 113 MARKET SHARE ANALYSIS OF IVD IN CHINA

FIG 114 GENERAL ELECTRIC COMPANY – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 115 KONINKLIJKE PHILIPS N.V. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 116 SIEMENS AG – REVENUE SPLIT BY DIVISION AND GEOGRAPHY (2023)

FIG 117 CANON MEDICAL SYSTEMS CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 118 SHIMADZU CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 119 FUJIFILM HOLDINGS CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 120 SAMSUNG ELECTRONICS CO. LTD. – REVENUE SPLIT BY BUSINESS DIVISION AND GEOGRAPHY (2023)

FIG 121 HOLOGIC INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 122 BIOMÉRIEUX S.A. – REVENUE SPLIT BY APPLICATION AND GEOGRAPHY (2023)

FIG 123 BIO-RAD LABORATORIES INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 124 THERMO FISHER SCIENTIFIC INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 125 BECTON, DICKINSON AND COMPANY – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 126 DANAHER CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 127 ABBOTT LABORATORIES – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 128 SIEMENS AG – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 129 QIAGEN N.V. – REVENUE SPLIT BY GEOGRAPHY AND CONSUMER CLASS (2023)

FIG 130 DIASORIN S.P.A. – REVENUE SPLIT BY GEOGRAPHY (2023)

FIG 131 F. HOFFMANN-LA ROCHE LTD. – REVENUE SPLIT BY DIVISION AND GEOGRAPHY (2023)

FIG 132 AGILENT TECHNOLOGIES INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)